688176 Jiangsu Yahong Meditech
- 7.95
- -0.27-3.28%
Jiangsu Yahong Meditech News
Yahong Meditech Says Cervical Lesion Drug Trial Shows Good Results
Express News | Yahong Medicine: APL-1702 clinical trial data selected for the 2024 International Papillomavirus Conference.
YaHong Pharmaceutical (688176): Revenue in the first three quarters exceeded expectations, APL-1706 approved for market launch.
1-3Q24 revenue higher than our expectationsCompany announced 1-3Q24 performance: revenue 0.139 billion yuan, single third quarter revenue 58.46 million yuan, revenue for the first three quarters higher than our expectations, mainly due to Dpart and Ououbi 4
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. Report for the Third Quarter of 2024
Yahong Pharmaceuticals (688176.SH): Net loss of 0.271 billion yuan in the first three quarters.
As of October 29, GeLongHui reported that Yuhong Medicine (688176.SH) achieved total operating income of 0.139 billion yuan in the first three quarters of 2024, an increase of 4537.79% year-on-year; net income attributable to the parent company's shareholders was -0.271 billion yuan; basic earnings per share was -0.48 yuan.
Yahong Pharmaceuticals accumulated revenue of 0.139 billion yuan in the first three quarters of this year, with two commercialized products continuing to ramp up production.
On the evening of October 29, YAHONG PHARMACEUTICAL (688176.SH) disclosed its third quarter report. The company achieved revenue of 58.4582 million yuan in the third quarter, a year-on-year increase of 1903.16%; for the first three quarters, the cumulative revenue was 0.139 billion yuan, a year-on-year increase of 4537.79%. The revenue growth is mainly attributed to the company starting to sell its drug Pipatinib Tablets (brand name: Dipatte) and Nilotinib Maleate Tablets (brand name: Ouyoubi) in the fourth quarter of 2023. Commercial promotion has steadily progressed during this reporting period, leading to an increase in sales volume.
Yahong Pharmaceutical (688176.SH): The clinical trial application for APL-2302 has been approved by the FDA.
Granger October 24th ǀ Asia Rainbow Pharmaceutical (688176.SH) announced that it has received a letter from the Food and Drug Administration (FDA) of the United States agreeing to conduct clinical trials of APL-2302, developed independently by the company, for the treatment of advanced solid tumors. APL-2302 is a ubiquitin-specific protease 1 (USP1) inhibitor developed independently by the company, which exerts anti-tumor effects through a mechanism of "synthetic lethality". Preclinical studies have shown good in vitro and in vivo activity of APL-2302 in tumor suppression as a monotherapy and in combination therapy. APL-2302 has the potential to become.
Express News | Yahong Pharma: APL-2302 clinical trial approved by FDA.
Yaohong Pharmaceuticals (688176.SH): has repurchased 1.4651% of the shares accumulated.
Galaxy Today, Yuhong Medicine (688176.SH) announced that as of September 30, 2024, the company has repurchased a total of 8,351,322 shares, accounting for 1.4651% of the total share capital. The highest purchase price was RMB 6.73 per share, the lowest price was RMB 4.99 per share, and the total amount paid was RMB 47.787 million (excluding stamp duty, transaction commission, and other transaction costs).
Yatai Pharmaceuticals (688176.SH): Granted 8.3201 million restricted stocks to 68 incentive recipients.
Golden stock September 27th, Aohong Pharmaceutical (688176.SH) announced that the company has set September 27, 2024 as the grant date, and will grant 8.3201 million restricted stocks to 68 incentive targets at a grant price of 3.06 yuan per share.
Jiangsu Yahong Meditech Finishes Phase 2 Trial for Muscle-Invasive Bladder Cancer Pre-Treatment Combo
Yahong Medical (688176.SH): The Phase II clinical trial of APL-1202 oral combination with Toripalimab as neoadjuvant treatment for muscle-invasive bladder cancer has been completed and has shown positive efficacy signals.
On September 25, Gelonghui announced that Yahong Medicine (688176.SH) disclosed the completion of Phase II clinical trial of APL-1202 oral combination with Toripalimab as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC) in stage I/II with positive therapeutic signals. The main objective of this Phase II clinical trial is to evaluate the safety and efficacy of APL-1202 in combination with Toripalimab compared to Toripalimab monotherapy as neoadjuvant therapy in MIBC subjects. The study population consists of subjects who are newly diagnosed with MIBC and planning to undergo radical cystectomy, intolerant or refusing to receive
Express News | Yuhong Medicine: APL-1202 combined with Trastuzumab achieves positive therapeutic signal in the treatment of MIBC.
Yahong Pharmaceuticals (688176): APL-1702 data readout
Event: On September 18, the company announced that the prospective, randomized, double-blind, placebo-controlled international multi-center Phase III clinical trial results for product APL-1702 for the treatment of high-grade squamous intraepithelial lesions (HSIL) of the cervix were selected.
Yahong Meditech Says APL1702 Drug's Trial Shows Positive Results; Shares Down 3%
Express News | Yahong Medicine: The results of the international multi-center Phase III clinical trial of product APL-1702 were selected for the 2024 International Photodynamic Therapy and Photodiagnostics Conference.
Yahong Pharmaceuticals-U(688176): Continuing to advance the progress of the pipeline
Event: Recently, the company released the 2024 interim report. In the first half of 2024, the company achieved a revenue of 80.493 million yuan, and a net income attributable to shareholders of the listed company of -0.184 billion yuan. APL-1702 submitted.
Yahong Medicine (688176.SH) released its semi-annual performance, with a net loss of 0.184 billion yuan.
Yahong Pharmaceutical (688176.SH) disclosed its 2024 interim report. During the reporting period, the company achieved revenue of 8,049...
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. 2024 Semi-Annual Report
Summary of the 2024 semi-annual report of Jiangsu Yahong Pharmaceutical Technology Co., Ltd.
Analysis
Price Target
No Data
No Data